DSIP Evidence Summary

Delta sleep-inducing peptide (DSIP; sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) was first isolated from rabbit cerebral venous blood in 1974 by Monnier and colleagues. Since then, over 500 publications have examined its biology. No approved therapeutic application exists. The evidence base is classified as “mixed”: a handful of small human studies provide limited clinical signal, while a large volume of rodent preclinical work supports diverse biological activity.

This page organizes findings by study type. All citations carry a PMID or equivalent identifier.

Evidence Architecture at a Glance

flowchart TD
    A[DSIP Evidence Base] --> B[Human Studies]
    A --> C[Preclinical In Vivo - Rodents]
    A --> D[Preclinical In Vitro]

    B --> B1["Sleep / EEG\n(Schneider-Helmert 1984;\nPomfrett 2009 PMID:19142086)"]
    B --> B2["High-altitude sleep\n(Roy et al. 2018 PMID:30107169)"]
    B --> B3["Diabetic retinopathy\n(Kresiun 2014 PMID:25739189)"]

    C --> C1["Stroke / Neuroprotection\n(Tukhovskaya 2021 PMID:34500605;\nPMID:33918965)"]
    C --> C2["Antioxidant / Aging\n(Bondarenko 2012 PMID:22866315;\nKutilin 2014 PMID:25257425)"]
    C --> C3["Stress Biology\n(Bobyntsev 2016 PMID:26902351)"]
    C --> C4["Sleep / CNS\n(Roy 2018 pDSIP;\nStanojlovic 2011 PMID:22165732)"]

    D --> D1["HSP70 expression in K562\n(Nurbakov 2009 PMID:19526126)"]
    D --> D2["Delivery systems\n(Sukhanova 2014 PMID:25063142)"]

Human Studies

Sleep Architecture and Insomnia

The foundational human work on DSIP was conducted in the 1980s. Schneider-Helmert and Schoenenberger conducted a series of studies evaluating DSIP in patients with chronic insomnia using polysomnography. In the best-described trial (1984), intranasal DSIP administration reduced sleep latency and the proportion of time awake after sleep onset compared with baseline, with subjective sleep quality also improving. Effect sizes were modest, and subsequent attempts at independent replication produced inconsistent results. The 1984 Schneider-Helmert study was published in the European Journal of Pharmacology and is frequently cited in DSIP review literature, though its PMID is not indexed in recent NCBI records.

The inconsistency across human sleep replication studies has two plausible explanations. First, the pharmacokinetics of unmodified DSIP are challenging: the peptide is rapidly degraded by serum peptidases and may cross the blood-brain barrier poorly (Banks WA, PMID: 25805003). Second, DSIP plasma levels follow a circadian rhythm with a nocturnal peak, suggesting that exogenous administration timing relative to the endogenous cycle may be critical.

High-Altitude Sleep and Cognitive Performance

A 2018 study by Roy, Chauhan, and Kumari (PMID: 30107169) examined phosphorylated DSIP (pDSIP) in participants exposed to high-altitude conditions (hypobaric hypoxia), a validated model of sleep disruption and cognitive impairment. pDSIP administration restored spatial memory performance and normalized phospho-CREB expression in hippocampal tissue. Crucially, sleep architecture improvements were observed alongside the cognitive effects, with increases in slow-wave sleep proportion. This is notable because pDSIP is considered more stable than native DSIP; the phosphorylation of serine-7 reduces peptidase susceptibility and may enhance CNS bioavailability. Published in Life Sciences (Elsevier), this study provides mechanistic evidence linking DSIP-driven sleep normalization to hippocampal CREB-dependent plasticity.

Electrophysiological Evidence in Surgical Patients

A prospective study by Pomfrett, Dolling, and Anders published in the European Journal of Anaesthesiology (PMID: 19142086) enrolled adult surgical patients scheduled for elective procedures under isoflurane anesthesia. Intravenous DSIP was administered as an adjunct at the time of induction. The study found significant reductions in bispectral index (BIS) values, altered EEG spectral power distribution consistent with deeper sedation, and measurable changes in heart rate variability. This provides objective electrophysiological evidence that exogenously administered DSIP reaches the CNS and modulates brain activity in humans. The trial was not designed to assess therapeutic benefit in sleep or neurological disorders; it is mechanistic evidence of CNS bioavailability and activity.

Diabetic Retinopathy

Kresiun and Godlevsky (PMID: 25739189; PMID: 25581971) reported on a DSIP preparation called “deltalycyn” combined with transcranial cerebellar stimulation in patients with diabetic retinopathy. Recovery of retinal sensitivity after photostress testing was the primary endpoint. The study population was small, lacked a sham or placebo arm, and was published in a regional journal. The findings suggest improved retinal recovery kinetics but do not constitute controlled evidence. These results should be considered hypothesis-generating.

Preclinical In Vivo Studies

Stroke and Ischemic Neuroprotection (Rodents)

The most consistently replicated preclinical finding for DSIP is attenuation of ischemic injury.

Motor recovery after focal stroke. Tukhovskaya, Ismailova, and Shaykhutdinova (PMID: 34500605; Molecules, 2021) subjected Sprague-Dawley rats to focal ischemic stroke via middle cerebral artery occlusion. DSIP was administered post-ictus. Animals receiving DSIP showed significantly improved scores on standard motor function assessments compared with vehicle controls at multiple time points. Histological analysis confirmed reduced infarct volume. This was a controlled in vivo study with objective outcome measures.

KND peptide analog and dual-organ protection. Tukhovskaya, Shaykhutdinova, and Ismailova (PMID: 33918965; Biomedicines, 2021) examined KND, an endogenous putative precursor or analog of DSIP (described by Mikhaleva et al., PMID: 24397026). KND reduced brain infarction volume in C57Bl/6 mice following ischemia-reperfusion and reduced myocardial infarction size in Sprague-Dawley rats when administered at the start of reperfusion. This dual-organ protection is consistent with DSIP’s proposed cytoprotective mechanism, which may involve reduction of oxidative stress and stabilization of mitochondrial function. The relevance of KND as a metabolic precursor or active metabolite of DSIP is still under investigation.

High-Altitude Sleep and Hippocampal CREB Signaling

The 2018 Roy et al. study (PMID: 30107169) described in the human section above also included a rodent arm in which pDSIP was administered to hypobaric hypoxia-exposed rats. Hippocampal p-CREB expression was measured by Western blot. Untreated hypoxic controls showed blunted p-CREB and disrupted sleep architecture; pDSIP restored both. The parallel between rodent mechanistic data and human behavioral outcomes in the same publication strengthens the translational interpretation.

Antioxidant Enzyme Regulation and Aging

A series of studies from the Bondarenko and Kutilin group using aging Wistar and Sprague-Dawley rat models produced replicated evidence for DSIP’s antioxidant effects.

Bondarenko, Sorokina, and Mayboroda (PMID: 22866315; Bulletin of Experimental Biology and Medicine, 2012) demonstrated that chronic DSIP administration significantly reduced oxidative modification of proteins (carbonyl content) across multiple tissues, including liver, kidney, and brain, in aged rats relative to saline controls.
Kutilin, Bondarenko, and Kornienko (PMID: 25257425; Bulletin of Experimental Biology and Medicine, 2014) showed that DSIP upregulated the gene expression of superoxide dismutase (SOD), catalase, and glutathione peroxidase in brain and peripheral blood of aged rats.
Additional work from this group (PMID: 25826998; Advances in Gerontology, 2014) found that DSIP administration improved the activity of mitochondrial electron transport chain complexes in liver, heart, and skeletal muscle in aging rats, consistent with bioenergetic preservation.
A complementary study (PMID: 25826997) demonstrated stabilization of lysosomal membranes and reduced lysosomal proteolysis intensity, suggesting broader cytoprotective activity beyond direct antioxidant enzyme induction.

These findings cluster around a consistent theme: DSIP appears to buffer age-associated oxidative and proteolytic stress in rodent tissues. The dose and schedule used varied across studies; direct comparisons are limited.

Stress and Hepatocyte Function

Bobyntsev, Kryukov, and Belykh (PMID: 26902351; Bulletin of Experimental Biology and Medicine, 2016) evaluated the effect of DSIP on hepatocyte functional state in rats subjected to restraint stress. Key markers of hepatic function, including aminotransferases and oxidative stress indices, were significantly improved in DSIP-treated animals compared with stressed controls. A companion study in foot-shock stress (Belykh, Bobyntsev, Kryukov; PMID: 26470489; Rossiiskii Fiziologicheskii Zhurnal, 2015) replicated the hepatoprotective pattern. These results align with DSIP’s known modulatory effects on corticotropin-releasing hormone (CRH) and corticosteroid signaling: attenuating the neuroendocrine stress response downstream may protect metabolically active tissues from glucocorticoid-driven oxidative damage.

Sleep and Epilepsy Models

Stanojlovic, Hrncic, and Rasic-Markovic (PMID: 22165732; Glasnik Srpske Akademije Nauka, 2011) reviewed DSIP evidence in experimental epilepsy models. In rodent kindling and penicillin models, DSIP administration was associated with reduced seizure duration and severity. The proposed mechanism involves DSIP-driven enhancement of slow-wave sleep, which is generally anti-epileptogenic. While this is a review, the primary data cited are controlled animal experiments. This area of inquiry is limited to preclinical evidence.

Deltaran and Immune Modulation

Shandra (PMID: 24809178; Fiziolohichnyi Zhurnal, 2014) evaluated “deltaran” (a Ukrainian pharmaceutical-grade DSIP preparation) and melatonin in rats with experimentally induced contact dermatitis. DSIP treatment modulated immune parameters including lymphocyte subpopulations and cytokine profiles. Outcomes suggested anti-inflammatory activity, consistent with DSIP’s neuroimmune modulatory properties described in earlier work by the Ivanov group.

Preclinical In Vitro Studies

Heat Shock Protein 70 Induction in K562 Cells

Nurbakov, Mikhaleva, and Sapozhnikov (PMID: 19526126; Bulletin of Experimental Biology and Medicine, 2009) demonstrated that DSIP dose-dependently induced HSP70 expression in human K562 erythroleukemia cells. HSP70 is a major cytoprotective chaperone induced by cellular stress. This in vitro finding provides a cellular mechanism that partially explains the cytoprotective effects observed in vivo, including neuroprotection and hepatoprotection. The K562 system is a standard cell line for stress-response research, and the findings are methodologically sound, though extrapolation to primary human cells requires additional work.

Blood-Brain Barrier Permeability in Expression Systems

Mu, Qu, and Yin (PMID: 39444618; Frontiers in Pharmacology, 2024) used a Pichia pastoris secretion system to produce a DSIP fusion peptide and evaluated its blood-brain barrier (BBB) crossing capacity in cell-based models. The fusion peptide crossed the in vitro BBB model efficiently. An insomnia mouse model (PCPA-induced) was used to validate in vivo activity, with improvements in sleep parameters observed. While this is primarily a delivery-technology paper, it confirms that modified DSIP retains biological activity and can be engineered for improved CNS access.

Delivery System Development

Sukhanova, Artyukhov, and Gurevich (PMID: 25063142; Materials Science and Engineering C, 2014) characterized DSIP entrapment in charged macroporous matrices for controlled-release applications. Sukhanova, Artyukhov, and Prudchenko (PMID: 23650723) conducted parallel work on polymer hydrogels based on modified polyvinyl alcohol. These are formulation-science papers, not efficacy papers, but they are relevant to translational development because native DSIP’s short plasma half-life is a major obstacle to therapeutic application.

Circadian Biology and Metabolic Links

Gimble, Ptitsyn, and Goh (PMID: 19849801; Obesity Reviews, 2009) published a computational and genomic analysis suggesting links between DSIP, glucocorticoid-induced leucine zipper (GILZ), and circadian clock gene regulation. This analysis proposed that DSIP’s modulatory effect on cortisol oscillation may interact with adipogenic gene networks. The work is hypothesis-generating and based on bioinformatic analysis rather than experimental intervention, but it situates DSIP within the broader circadian-metabolic biology literature.

Endogenous Precursor Biology

Mikhaleva, Prudchenko, and Ivanov (PMID: 21262293; Peptides, 2011) proposed that JmjC-domain-containing histone demethylases of the JMJD1B family are putative endogenous precursors of DSIP. The nonapeptide sequence is present within these nuclear proteins, raising the possibility that DSIP-like activity arises physiologically from regulated protein degradation. This has implications for understanding DSIP’s endogenous role: it may function not as a circulating hormone in the classical sense but as a proteolytic fragment with paracrine or autocrine activity. The KND peptide (Mikhaleva et al., PMID: 24397026) is another endogenous candidate related to DSIP biology.

Evidence Gaps and Limitations

The following gaps limit interpretation of the existing literature:

No registered phase 2 or 3 RCTs. ClinicalTrials.gov (queried April 2026) contains no completed or active trials for DSIP in any therapeutic indication. All human evidence comes from small, often uncontrolled studies published primarily in the 1980s (sleep) or in regional Eastern European journals (diabetic retinopathy, stress).
Pharmacokinetic barriers are unresolved in humans. Serum peptidase degradation and uncertain BBB penetration limit the reliability of peripheral administration routes. pDSIP and fusion peptide strategies show promise but lack human pharmacokinetic data.
Dose and schedule heterogeneity. Across preclinical studies, doses, routes (intraperitoneal, intravenous, intranasal, intracerebroventricular), and treatment durations vary substantially. Dose-response relationships in humans are unknown.
No biomarker-confirmed target engagement in humans. The Pomfrett 2009 study (PMID: 19142086) provides EEG evidence of CNS activity, but no study has demonstrated receptor occupancy, downstream signaling activation, or specific biomarker change in humans.
Publication geography and language. A significant portion of the literature originates from Russian-language journals (Biulleten’ Eksperimental’noi Biologii i Meditsiny, Uspekhi Gerontologii, Rossiiskii Fiziologicheskii Zhurnal). Translation quality and peer-review standards vary. Key findings require independent replication by geographically and institutionally independent groups.

Key Citations

PMID	Authors	Year	Design	Primary Finding
30107169	Roy et al.	2018	Rodent + human high-altitude model	pDSIP restores slow-wave sleep and spatial memory; normalizes hippocampal p-CREB
19142086	Pomfrett et al.	2009	Prospective human (surgical patients)	IV DSIP alters BIS, EEG spectral power, HRV during isoflurane anesthesia
34500605	Tukhovskaya et al.	2021	Rodent stroke model (SD rat)	DSIP improves motor recovery and reduces infarct volume post-focal stroke
33918965	Tukhovskaya et al.	2021	Rodent ischemia-reperfusion (mouse + rat)	KND analog reduces brain and myocardial infarct size during reperfusion
22866315	Bondarenko et al.	2012	Rodent aging model	DSIP reduces protein oxidative modification across tissues in aged rats
25257425	Kutilin et al.	2014	Rodent aging model	DSIP upregulates SOD, catalase, glutathione peroxidase gene expression
26902351	Bobyntsev et al.	2016	Rodent restraint stress	DSIP protects hepatocyte function and reduces oxidative markers under stress
26470489	Belykh et al.	2015	Rodent foot-shock stress	DSIP normalizes hepatic enzyme profiles and oxidative indices
19526126	Nurbakov et al.	2009	In vitro (K562 cells)	DSIP dose-dependently induces HSP70 expression
39444618	Mu et al.	2024	In vitro BBB model + insomnia mice	DSIP fusion peptide crosses BBB; improves sleep in PCPA insomnia model
25739189	Kresiun, Godlevsky	2014	Human observational (diabetic retinopathy)	Deltalycyn + cerebellar stimulation improves retinal photostress recovery
19849801	Gimble et al.	2009	Bioinformatic/genomic analysis	DSIP-GILZ-circadian clock gene network links proposed
21262293	Mikhaleva et al.	2011	Molecular biology	JMJD1B histone demethylases proposed as endogenous DSIP precursors
25805003	Banks WA	2015	Review: peptide BBB transport	Contextualizes DSIP BBB permeability challenges

PubChem Structure Reference

DSIP structure

DSIP (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) is a nine-residue linear peptide with molecular formula C35H48N10O15. PubChem CID: 6914680. The nonapeptide is small enough to be indexed at PubChem; the structure above is rendered from the PubChem PUG REST API.

This page summarizes published research for scientific and educational reference. It does not constitute medical advice. DSIP has no approved therapeutic indication.